Long-term Bone Mineral Density Changes in Antiretroviral-Treated HIV-Infected Individuals.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 27330053.
- Also identified by DOI 10.1093/infdis/jiw204 and PMC identifier 4957444.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We compared adjusted bone mineral density (BMD) changes between human immunodeficiency virus (HIV)-infected individuals during the first approximately 7.5 years after antiretroviral therapy (ART) initiation and HIV-uninfected controls. HIV-infected individuals (n = 97) had significantly greater adjusted BMD decline than controls (n = 614) during the first 96 weeks of ART. Subsequently, the rate of BMD decline slowed in HIV-infected individuals but remained greater than the rate of decline in HIV-uninfected individuals at the lumbar spine but not at the hip. In HIV-infected individuals after 96 weeks, no HIV- or treatment-related characteristic was associated with BMD loss, but lower lean body mass was associated with greater BMD loss at both lumbar spine and hip.
Medical subject headings
- Anti-Retroviral Agents
- Bone Density
- HIV Infections